Indication
Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.
Loading your page…
Loading your page…
Lambert-Eaton Myasthenic Syndrome;Paraneoplastic Syndromes, Nervous System;Nervous System Neoplasms;Paraneoplastic Syndromes;Nervous System Diseases;Autoimmune Diseases of the Nervous System;Neurodegenerative Diseases;Neuromuscular Diseases;Neuromuscular Junction Diseases;Immune System Diseases;Autoimmune Diseases;Autoimmune Diseases of the Nervous System;Cancer;Neoplasms
Marketing Authorisation Holder: SERB SA
EMA Authorisation: 19/05/2022
INN: amifampridine
AI Drug & Interaction Analysis
Free account required
Ask Osler about Amifampridine SERB: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.